PRKCI and cancer: The diverse oncogenic functions of PKCι mediated through PB1 protein interactions in multiple different cancers that will be activated through CNGs of the 3q amplicon make PKCι an exciting therapeutic target for small-molecule inhibitors and PROTAC development.